Medical Condition News

RSS

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.

3 Nov 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

New tool can particularly sort tumor-causing cancer cells

A new tool developed by scientists at The Methodist Hospital separates tumor-causing cancer cells from more benign cells by subjecting the cells to a microscopic game of Plinko -- except only the squishiest cells make it through.

3 Nov 2012

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California.

3 Nov 2012

Some types of bariatric surgery may cause bone loss, say endocrinologists

Bariatric surgery, which significantly curtails the amount of food a person can eat, is the most effective treatment against obesity and is being recognized as a potentially valuable tool in the fight against diabetes related to obesity.

3 Nov 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.

3 Nov 2012

Autism interventions are supported by varying levels of evidence, reveals new RAND study

Interventions designed to improve core deficits in children with autism spectrum disorders are supported by varying levels of evidence, highlighting the need for well-designed studies to better evaluate the interventions, according to a new RAND Corporation study.

3 Nov 2012

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.

3 Nov 2012

Research roundup: Lowering health costs of the poorest sick; Local variations in health spending

Olmstead County, Minn., which earlier required just restaurants to be smoke-free, enacted a law in 2007 that banned smoking in all workplaces. Researchers reported "a substantial decline in the incidence of MI from 18 months before the smoke-free restaurant law was implemented to 18 months after the comprehensive smoke-free workplace law was implemented 5 years later.

3 Nov 2012

Health Net provides public with information on how to help prevent diabetes

With November being American Diabetes Month, Health Net, Inc. is providing the public with information on how to help prevent diabetes and how to help live an active lifestyle after being diagnosed with the condition.

3 Nov 2012

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD), Mayo Clinic researchers say.

3 Nov 2012

Researchers develop new technique to predict enzymes known to accelerate diseases

Predicting how atherosclerosis, osteoporosis or cancer will progress or respond to drugs in individual patients is difficult.

3 Nov 2012

Cannabis use causes temporary cognitive breakdown in non-psychotic individuals: Study

Researchers at the University of Bergen in Norway have found new support for their theory that cannabis use causes a temporary cognitive breakdown in non-psychotic individuals, leading to long-term psychosis.

3 Nov 2012

People's reactions to stressors determine health consequences, say Penn State researchers

Contrary to popular perception, stressors don't cause health problems -- it's people's reactions to the stressors that determine whether they will suffer health consequences, according to researchers at Penn State.

3 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

3 Nov 2012

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.

3 Nov 2012

Studies provide new information on diet and blood pressure in kidney disease patients

Three studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on diet and blood pressure in kidney disease patients.

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.

3 Nov 2012

Medical Condition News

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

New tool can particularly sort tumor-causing cancer cells

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Some types of bariatric surgery may cause bone loss, say endocrinologists

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

Autism interventions are supported by varying levels of evidence, reveals new RAND study

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

Research roundup: Lowering health costs of the poorest sick; Local variations in health spending

Health Net provides public with information on how to help prevent diabetes

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Researchers develop new technique to predict enzymes known to accelerate diseases

Cannabis use causes temporary cognitive breakdown in non-psychotic individuals: Study

People's reactions to stressors determine health consequences, say Penn State researchers

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Studies provide new information on diet and blood pressure in kidney disease patients

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Latest News